The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients
By J. Christensen, Jill Hallin, Lars D. Engstrom, Lauren N. Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, B. R. Baer and 24 more. Cancer Discovery, 2019
962 citations recorded by the source corpus.
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRASG12C and inhibits KRAS-dependent signaling. MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) of KRASG12C-positive cell line- and patient-derived xenograft models from multiple tumor types and objective responses have been observed in KRASG12C-positive lung and colon adenocarcinoma patients. Comprehensive pharmacodynamic and pharmacogenomic profiling in sensitive and partially resistant non-clinical models identified mechanisms implicated in limiting anti-tumor activity including KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence. These factors included activation of RTKs, bypass of KRAS dependence, and genetic dysregulation of cell cycle. Combinations of MRTX849 with agents that target RTKs, mTOR, or cell cycle demonstrated enhanced response and marked tumor regression in several tumor models, including MRTX849-refractory models.
Subfields: Cell Biology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/ea93072ecabd7f1aff015f255c8e7366c80187c9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Harnessing multimodal data integration to advance precision oncology (2021, background): “Targeted cancer therapies are continually being added to the clinical arena; for example, ongoing clinical trials of KRAS-G12C inhibitors 50,51 and the PI3Kα-specific inhibitor targeting PIK3CA mutations 52 in lung cancer and breast cancer, respectively.”